Atsena Therapeutics
Patrick Ritschel is an experienced executive and entrepreneur with over 25 years of experience in business management, business development and technology licensing. Mr. Ritschel was co-founder and President of StrideBio, a gene therapy company based in Durham, North Carolina, and continues to serve on the StrideBio Board of Directors. Prior to StrideBio, he was an angel investor and played an instrumental role in the formation of gene therapy company Bamboo Therapeutics (acquired by Pfizer in 2016). Mr. Ritschel spent his early career with Monsanto Enviro-Chem Systems, Inc. in St. Louis and Hong Kong. He participated in the management buyout of the Enviro-Chem subsidiary in 2005, and upon the subsequent sale of the company to DuPont in 2010, he joined DuPont as Director of Business Development.
He is active in the rare disease community and currently serves on the Board of Directors of the Friedreich’s Ataxia Research Alliance (FARA).
Mr. Ritschel holds a B.S. in Mechanical Engineering from the University of Illinois Urbana-Champaign, cum laude, and an M.B.A. from Washington University in St. Louis.
This person is not in any offices
Atsena Therapeutics
Atsena Therapeutics is a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness. They have an ongoing Phase I/II clinical trial evaluating a potential therapy for one of the most common causes of blindness in children. Their additional pipeline of leading preclinical assets is powered by an adeno-associated virus (AAV) technology platform tailored to overcome significant hurdles presented by inherited retinal disease.